Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19
The hypoxia and profound inflammatory response associated with the pneumonitis observed with the SARS-CoV-2 virus responsible for the recent COVID-19 pandemic has overwhelmed intensive care facilities in the epicenters of infection including Wuhan, China, Northern Italy and in the USA, the Seattle a...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | English |
| Published: |
BMJ
2020
|
| Online Access: | https://hdl.handle.net/1721.1/124891 |
| _version_ | 1811090701516013568 |
|---|---|
| author | Spranger, Stefani |
| author2 | Massachusetts Institute of Technology. Department of Biology |
| author_facet | Massachusetts Institute of Technology. Department of Biology Spranger, Stefani |
| author_sort | Spranger, Stefani |
| collection | MIT |
| description | The hypoxia and profound inflammatory response associated with the pneumonitis observed with the SARS-CoV-2 virus responsible for the recent COVID-19 pandemic has overwhelmed intensive care facilities in the epicenters of infection including Wuhan, China, Northern Italy and in the USA, the Seattle and New York City areas. The Society for Immunotherapy of Cancer (SITC) stands along with and supports our colleagues in emergency departments, intensive care units (ICUs) and inpatient wards in the global effort to overcome this unprecedented pandemic. ©2020 |
| first_indexed | 2024-09-23T14:50:31Z |
| format | Article |
| id | mit-1721.1/124891 |
| institution | Massachusetts Institute of Technology |
| language | English |
| last_indexed | 2024-09-23T14:50:31Z |
| publishDate | 2020 |
| publisher | BMJ |
| record_format | dspace |
| spelling | mit-1721.1/1248912022-10-01T22:52:38Z Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 Spranger, Stefani Massachusetts Institute of Technology. Department of Biology Koch Institute for Integrative Cancer Research at MIT The hypoxia and profound inflammatory response associated with the pneumonitis observed with the SARS-CoV-2 virus responsible for the recent COVID-19 pandemic has overwhelmed intensive care facilities in the epicenters of infection including Wuhan, China, Northern Italy and in the USA, the Seattle and New York City areas. The Society for Immunotherapy of Cancer (SITC) stands along with and supports our colleagues in emergency departments, intensive care units (ICUs) and inpatient wards in the global effort to overcome this unprecedented pandemic. ©2020 2020-04-27T20:09:47Z 2020-04-27T20:09:47Z 2020-01 2020-04-27T17:20:36Z Article http://purl.org/eprint/type/JournalArticle 2051-1426 https://hdl.handle.net/1721.1/124891 Ascierto, Paolo Antonio, et al., "Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19." Journal for ImmunoTherapy of Cancer 8, 1 (Jan. 2020): no. e000878 doi 10.1136/jitc-2020-000878 ©2020 Author(s) en 10.1136/jitc-2020-000878 Journal for ImmunoTherapy of Cancer Creative Commons Attribution NonCommercial License 4.0 https://creativecommons.org/licenses/by-nc/4.0/ application/pdf BMJ BMJ |
| spellingShingle | Spranger, Stefani Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 |
| title | Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 |
| title_full | Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 |
| title_fullStr | Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 |
| title_full_unstemmed | Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 |
| title_short | Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 |
| title_sort | insights from immuno oncology the society for immunotherapy of cancer statement on access to il 6 targeting therapies for covid 19 |
| url | https://hdl.handle.net/1721.1/124891 |
| work_keys_str_mv | AT sprangerstefani insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 |